Shenzhen Kangtai Biological Products Co., Ltd.
http://www.biokangtai.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shenzhen Kangtai Biological Products Co., Ltd.
Recbio First Biotech To Brave A Hong Kong IPO In 2022
Chinese vaccine maker Recbio hopes an IPO in Hong Kong will bring investor attention to its mRNA COVID vaccine with potential against the Omicron variant.
China Authorizes New Inactivated Vaccine Amid Doubt Over Sinopharm Jabs
A new emergency authorization marks China’s fourth approval for inactivated COVID-19 vaccines, despite lingering doubts over the protection offered by the technology and surging cases in one of the most vaccinated countries where Sinopharm’s inactivated vaccines are widely used.
China's COVID Vaccine Charm Offensive: Can It Leave Scandal-Ridden Past Behind?
As China gears up to roll out millions of doses of its own vaccines to help fend off the coronavirus around the world, a scandal-ridden past continues to haunt the aspiring sector but is fading with improved regulation.
China Vaccine Sector Steams To COVID Finish Line Despite Scandal-Ridden Past
When a high-profile regulatory official in China was sentenced to 10 years in prison, at least five vaccine makers were found to have paid millions in bribes, although none were rigorously prosecuted. Three years later, as the country gears up for worldwide roll-out of its COVID-19 vaccines, many wonder if there are haunting glimmers from the past.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- Biokangtai
- Beijing Minhai Biotechnology Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice